<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03772574</url>
  </required_header>
  <id_info>
    <org_study_id>H18-02855</org_study_id>
    <nct_id>NCT03772574</nct_id>
  </id_info>
  <brief_title>Preoxygenation Using THRIVE Versus Facemask in Parturients</brief_title>
  <official_title>Preoxygenation Using THRIVE and Facemask Oxygenation in Parturients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the duration for pre-oxygenation using THRIVE and facemask for
      parturients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We aim to determine the duration required for THRIVE and facemask preoxygenation in
      parturients for them to achieve ETO2 &gt;90%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preoxygenation duration</measure>
    <time_frame>Maximum 8 minutes</time_frame>
    <description>Duration to achieve EtO2 &gt;=90% after tidal volume breathing using THRIVE and facemask pre-oxygenation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Preoxygenation</condition>
  <arm_group>
    <arm_group_label>THRIVE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>THRIVE preoxygenation (tidal volume breathing with the OptiFlow system applied at 100% oxygen).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Facemask</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Facemask preoxygenation (tidal volume breathing via a face mask set at 100% oxygen).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Facemask preoxygenation</intervention_name>
    <description>Standard facemask preoxygenation</description>
    <arm_group_label>Facemask</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>THRIVE preoxygenation</intervention_name>
    <description>Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).</description>
    <arm_group_label>THRIVE</arm_group_label>
    <other_name>THRIVE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant patients ≥36 weeks gestation.

          -  Non-laboring patients admitted for elective Cesarean delivery under neuraxial
             anesthesia or induction of labor.

          -  American Society of Anesthesiologists (ASA) class 2.

        Exclusion Criteria:

          -  Any medical conditions that are likely to affect gas exchange.

          -  Obstructed nasal passage.

          -  Unable to tolerate a tight fitting facemask.

          -  Body Mass Index ≥40 kg/m2.

          -  Patients who are in active labor (i.e. cervical dilation ≥4cm).

          -  Patients who are unable to give informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anton Chau, MD MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James D Taylor, BSc</last_name>
    <phone>604-875-2424</phone>
    <phone_ext>6076</phone_ext>
    <email>james.taylor1@phsa.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelly Au, BSc MD</last_name>
    <phone>604-875-2424</phone>
    <phone_ext>6076</phone_ext>
    <email>kelly.au@cw.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BC Women's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James D Taylor, BSc</last_name>
      <phone>604-875-2424</phone>
      <phone_ext>6076</phone_ext>
      <email>james.taylor1@phsa.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Au, BSc MD</last_name>
      <phone>604-875-2424</phone>
      <phone_ext>6076</phone_ext>
      <email>kelly.au@cw.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Anton Chau, MD MMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelly Au, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Shippam, MB BCh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Taylor, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arianne Albert, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 8, 2018</study_first_submitted>
  <study_first_submitted_qc>December 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2018</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Anton Chau</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

